AZBio welcomes new leaders: Arizona BioIndustry Association Elects IBM’s Ennesser and Ventana Medical Systems’ Miller to Board of Directors and Galster as Chair.
The Arizona BioIndustry Association board of directors elected two new board
members and a new chairman at its statewide board meeting.
Joining the board of directors are Joseph “Jay” Ennesser and Dr. Phillip C. Miller.
Ennesser is Vice President, Smarter and Innovation Alliances, and Senior Location Executive for IBM Phoenix. Ennesser joined IBM in 1980 and has progressed through the organization with specializations in product life cycle management, supply chain management and ECAD offerings. He is also on the board of directors for the National Association of Strategic Alliance Professionals.
Miller is Senior Vice President Technology and Applied Research for Ventana Medical Systems, Inc., a member of the Roche Group, a position he has held since 2002. From 1988 – 1994 he was also Ventana’s Vice President R&D, and was the acting CEO in 1990. He left Ventana in 1994 for a position in California before returning to Southern Arizona. Miller has over 30 years of experience in the in vitro diagnostics industry, primarily in the development and commercialization of technology-based products.
Glen Galster, co-founder of Northern Arizona’s Algae Biosciences, Incorporated was elected Chairman of the AZBio Board of Directors. Algae Biosciences Incorporated, a development stage biotechnology company, engages in the growth, production, and sale of microalgae for the nutraceutical, pharmaceutical, and biofuel markets in the United States. Algae Biosciences, Incorporated was founded in 2002 and is based in Overgaard, Arizona.
The Arizona BioIndustry Association, “AZBio,” is a community made up of member organizations in business, research, government and other professions involved in biosciences from across the state of Arizona and in partnership with other leading organizations across the country. AZBio supports the growth of Arizona’s bioscience community by providing access to the key resources, connections, and information that support members’ ability to connect, collaborate, innovate and succeed thus supporting the growth of a thriving economic ecosystem for Arizona’s Bioscience Industry.
“AZBio is honored to have Jay Ennesser and Dr. Phil Miller join our leadership team and to have Glen Galster step up to leadership at a higher level in our organization,” shared AZBio’s Joan Koerber-Walker. “Each brings a unique set of talents and experience to an already talented and committed board of directors. Together we can move Arizona’s bioscience community forward faster. We are also deeply grateful to departing board members Dr. Gary Greenburg (representing the Arizona Science Foundation), Dr. Jack H. Dean (representing Drug Development Advisors) and Christine McAuliffe (representing Polsinelli Shughart). All three leaders are strong advocates for our bioscience community and were valued members of the team. We wish them continued success in their new endeavors.”
Miller, Ennesser and Galster will all be playing active roles in the upcoming AZBioExpo taking place on October 14, 2011 at the Sheraton Wild Horse Pass in Chandler, Arizona. Galster will present “Bio Goes Green and Gets Green” as part II of a two part session on the development of a new company and its successful launch on the Toronto Venture Exchange. (Part I of the series will be hosted by
representatives from the TMX Group which owns and operates the Toronto Stock Exchange and the TSX Venture Exchange.) Ennesser and Miller will be
featured on the closing panel: Looking Forward: A Global Perspective. Joining them on the panel will be Janet Spear of Celegene, Dr. Ken Wertman of sanofi-aventis, and Bosserman of Medelis.
Other Arizona BioIndustry Association board of director members are: Glen Galster (Chair) President, Algae Biosciences Incorporated), David McCaleb (Secretary), President, McCaleb Associates, Inc.; Robert Davis, Sr. Vice President, Industrial and Investment Services, Grubb & Ellis Company; William Gartner, President and CEO, Provista Life Sciences; Gordon Goodyear, President, 3d Biosurfaces, Jim Harris, Vice President, Translational Genomics Research Institute; Robert E. Kennedy, CFO, RXI Pharmaceuticals Corp.; Joan
Koerber-Walker, President and CEO, Arizona BioIndustry Association; Pete
Manspeaker, President, Vision Quest Bioscience; Ralph Martel, Chief Technology Officer, Arizona Biosignatures Laboratory, the Critical Path Institute; Jon McGarity, President and CEO, EthiX Associates; Michael Mobley, President and CEO, M.J. Mobley Consulting; Jacqueline M. Nicol, Director of IP & Partnering, BioVigilant Systems, Inc.; Randal Schulhauser, Sr. Manager of Technology & Business Development, Medtronic-Tempe Campus; Janet Spear, Phoenix Plant Manager, Celgene Corporation; and, Sandra Watson, Chief Operating Officer, Arizona Commerce Authority.
Additional information about the Arizona BioIndustry Association and Arizona’s bioscience community may be found at its website or experienced firsthand as the community gathers from across the state on October 13 & 14, 2011 for the AZBio Awards and Expo at the Sheraton Wild Horse Pass in Chandler, Arizona. For more details visit www.AZBIO.org and www.AZBioExpo.com.
For more information please visit http://www.ibm.com .
About Ventana Medical Systems, Inc.
Ventana Medical Systems, Inc. (“VMSI”) (SIX: RO, ROG; OTCQX: RHHBY), a member of the Roche Group, innovates and manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. VENTANA solutions are used in clinical histology and drug development research laboratories worldwide. The company’s “Smart Systems” – intuitive, integrated staining and workflow management platforms that optimize laboratory efficiencies to reduce errors – support diagnosis and inform treatment decisions for anatomic pathology professionals. Together with Roche, VMSI is driving personalized medicine through accelerated drug discovery and the development of “companion diagnostics” to identify the patients most likely
to respond favorably to specific therapies. Visit http://www.ventana.com to
learn more. VENTANA and the VENTANA logo are trademarks of Roche
For additional information regarding this press release, contact: Joan Koerber-Walker, 480-332-9636, firstname.lastname@example.org